Fifth Third Bancorp Grows Stake in Integra LifeSciences Holdings Corporation $IART

Fifth Third Bancorp boosted its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 12,812.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 53,976 shares of the life sciences company’s stock after acquiring an additional 53,558 shares during the quarter. Fifth Third Bancorp’s holdings in Integra LifeSciences were worth $508,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IART. Global Retirement Partners LLC bought a new stake in shares of Integra LifeSciences in the 4th quarter valued at approximately $25,000. Osaic Holdings Inc. increased its position in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Integra LifeSciences by 595.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after purchasing an additional 6,814 shares during the last quarter. Virtu Financial LLC purchased a new stake in Integra LifeSciences during the 4th quarter valued at $124,000. Finally, Sequoia Financial Advisors LLC raised its holdings in Integra LifeSciences by 27.4% during the 1st quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock valued at $134,000 after buying an additional 3,059 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

More Integra LifeSciences News

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra reported second-quarter adjusted EPS of $0.56, above the $0.48 analyst consensus and up from $0.45 a year earlier. Revenue of $418.8 million was slightly ahead of the $417.5 million estimate. Integra LifeSciences Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year 2026 EPS guidance of $2.40 to $2.50 centers on $2.45, matching consensus, while revenue guidance of approximately $1.7 billion remains in line with expectations. Third-quarter revenue guidance of $410 million to $425 million also brackets the $417.3 million consensus estimate. Integra Q2 2026 Earnings Call Transcript
• Neutral Sentiment: UBS initiated coverage with a Neutral rating and a $19 price target, implying potential upside from recent trading levels but signaling that the valuation and operating outlook appear broadly balanced. UBS coverage report
• Neutral Sentiment: Technical screens identified IART as a potential breakout stock trading near its 52-week high, which may attract momentum-focused investors; however, this does not change the company’s fundamental outlook. Stocks Showing Breakout Potential
• Negative Sentiment: The earnings beat was relatively modest at the revenue level, and the company continues to report a negative net margin. With quarterly and full-year guidance essentially matching expectations rather than being raised materially, investors may have viewed the update as lacking a significant upside catalyst, contributing to the stock’s decline.

Integra LifeSciences Trading Down 16.5%

Shares of NASDAQ IART opened at $16.49 on Thursday. Integra LifeSciences Holdings Corporation has a fifty-two week low of $8.70 and a fifty-two week high of $20.49. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -2.55, a PEG ratio of 1.37 and a beta of 1.22. The business’s 50 day moving average price is $17.63 and its 200-day moving average price is $13.42.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. The company had revenue of $418.76 million during the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, sell-side analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IART. BMO Capital Markets initiated coverage on Integra LifeSciences in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price target for the company. UBS Group initiated coverage on shares of Integra LifeSciences in a research note on Tuesday. They issued a “neutral” rating and a $19.00 target price on the stock. Wall Street Zen lowered shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. Truist Financial lifted their price target on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Finally, Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $18.43.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.